Literature DB >> 2643221

Cardiopulmonary bypass with profound hypothermia. An optimal preservation method for multiorgan procurement.

W A Baumgartner1, G M Williams, C D Fraser, D E Cameron, T J Gardner, J F Burdick, S Augustine, P D Gaul, B A Reitz.   

Abstract

Numerous techniques have been devised for the harvesting of individual organs during a multiorgan procurement operation. Cardiopulmonary bypass with profound hypothermia (PH) has been employed in successful harvesting of heart-lung, kidney, pancreas, and liver grafts. This report summarizes our experience using CPB-PH for the harvesting of multiple organs from 10 brain-dead donors during the period from July 1983 to January 1988. Organs harvested included 10 heart-lungs, 17 kidneys (3 kidneys were not harvested due to anatomy and elevated creatinine), 1 liver, and 1 pancreas. Mean ischemic time for the distantly procured heart-lung grafts was 281 +/- 10 min. Adequate pulmonary function, as assessed by arterial blood gases, was observed in each heart-lung recipient (mean PO2 was 119 +/- 46 mmHg, 164 +/- 47 mmHg, 130 +/- 30 mmHg, 114 +/- 26 mmHg at immediate post-CPB, 6 hr postop, 24 hr postop, and postextubation, respectively). Mean length of intubation was 34 +/- 8 hr. Mean creatinines of kidney recipients at days 2, 7, and current creatinine were 7.4 +/- 3.6 mg%, 3.6 +/- 2.4 mg%, and 1.6 +/- 0.66 mg%, respectively. Eight kidney recipients (47%) required dialysis, (2 patients required only a single dialysis). Ninety-four percent of the kidney transplant patients are alive, and 88% (15/17) have functioning kidneys. One liver and 1 pancreas were harvested during this time period. Preservation was satisfactory in both the pancreas (Johns Hopkins Hospital) and liver (Dr. Thomas Starzl, personal communication). The technique of CPB-PH has resulted in excellent function of heart-lung grafts. Follow-up of the transplanted kidneys, liver, and pancreas utilizing this technique shows equal or better function compared with standard techniques. This technique offers other advantages in addition to satisfactory multiorgan preservation. Placement of an unstable patient on CPB ensures adequate organ perfusion and allows for a gradual yet uniform cooling of all organ systems. Cooling to a core temperature of 10-15 degrees C requires 30 min, during which time preliminary intraabdominal and mediastinal dissection can be carried out. Following cessation of CPB and subsequent exsanguination, organs can be more easily dissected in a near-bloodless field. This technique does not preclude additional crystalloid organ flushing. Since multiorgan procurement occurs with virtually every donor, this technique may be the optimal method providing excellent preservation, ease of dissection, and better control of hemodynamics during the operation.

Entities:  

Mesh:

Year:  1989        PMID: 2643221     DOI: 10.1097/00007890-198901000-00027

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  5 in total

1.  [The concept of lung and heart-lung preservation within the scope of multiple organ procurement].

Authors:  H R Zerkowski; N Doetsch; A Hellinger; J C Reidemeister
Journal:  Langenbecks Arch Chir       Date:  1991

Review 2.  Preservation solution for lung transplantation.

Authors:  Yoshinori Okada; Takashi Kondo
Journal:  Gen Thorac Cardiovasc Surg       Date:  2009-12

Review 3.  Ischemia/Reperfusion.

Authors:  Theodore Kalogeris; Christopher P Baines; Maike Krenz; Ronald J Korthuis
Journal:  Compr Physiol       Date:  2016-12-06       Impact factor: 9.090

Review 4.  Cell biology of ischemia/reperfusion injury.

Authors:  Theodore Kalogeris; Christopher P Baines; Maike Krenz; Ronald J Korthuis
Journal:  Int Rev Cell Mol Biol       Date:  2012       Impact factor: 6.813

5.  Histopathological evaluation of the role of negative electrical charge on renal ischemia/reperfusion injuries on brain and heart tissues in rat.

Authors:  Sara Dehyadegari; Mohammad Mehdi Oloumi; Shahrzad Azizi
Journal:  Vet Res Forum       Date:  2020-03-15       Impact factor: 1.054

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.